Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Sarah Stanhope"'
Autor:
Brendan Curti, Koustubh Ranade, Laura Collins, Marlana Orloff, Emma Leach, Sarah Stanhope, Adel Benlahrech, Kevin Kim
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/631b1a31539341579031893888fc8433
Autor:
Koustubh Ranade, Laura Collins, Duncan Gascoyne, Rahul Khanolkar, Revashnee Naidoo, Esra Güç, Emma Leach, Sarah Stanhope, Adel Benlahrech
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/efe704b395a44aa6a3ca56cd2e01c49f
Autor:
Richard D. Carvajal, Paul Nathan, Joseph J. Sacco, Marlana Orloff, Leonel F. Hernandez-Aya, Jessica Yang, Jason J. Luke, Marcus O. Butler, Sarah Stanhope, Laura Collins, Cheryl McAlpine, Chris Holland, Shaad E. Abdullah, Takami Sato
Publikováno v:
Journal of Clinical Oncology. 40:1939-1948
PURPOSEThis phase I study aimed to define the recommended phase II dose (RP2D) of tebentafusp, a first-in-class T-cell receptor/anti-CD3 bispecific protein, using a three-week step-up dosing regimen, and to assess its safety, pharmacokinetics, pharma
Autor:
Mario Sznol, Ita O’Kelly, Jacob Hurst, Sion Lewis, Sarah Stanhope, Revashnee Naidoo, Emma Leach, Antonella Vardeu, Avinash Gupta, Omid Hamid, Alexander N. Shoushtari, Alan Anthoney, Thomas R. Jeffry Evans, Neil M. Steven, Jeffrey R. Infante, Pippa Corrie, Victoria K. Woodcock, Cheryl McAlpine, Mark R. Middleton
Supplementary material
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c150f85250c5fc5cf0680722bad89c5b
https://doi.org/10.1158/1078-0432.22476341.v1
https://doi.org/10.1158/1078-0432.22476341.v1
Autor:
Mario Sznol, Ita O’Kelly, Jacob Hurst, Sion Lewis, Sarah Stanhope, Revashnee Naidoo, Emma Leach, Antonella Vardeu, Avinash Gupta, Omid Hamid, Alexander N. Shoushtari, Alan Anthoney, Thomas R. Jeffry Evans, Neil M. Steven, Jeffrey R. Infante, Pippa Corrie, Victoria K. Woodcock, Cheryl McAlpine, Mark R. Middleton
Purpose:Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain, which redirects T cells to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ccbf030ab20eb31d6aefca0fa390978
https://doi.org/10.1158/1078-0432.c.6529373
https://doi.org/10.1158/1078-0432.c.6529373
Autor:
Alexander Greenshields Watson, Camille Britton-Rivet, Sarah Stanhope, Laura Collins, Koustubh Ranade, Adel Benlahrech
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Laura Collins, Alexander Greenshields Watson, Shaad Abdullah, Sarah Stanhope, Koustubh Ranade, Emma Leach
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Marcus O. Butler, Takami Sato, Friedegund Meier, Ramakrishna Edukulla, Sarah Stanhope, Fraser S. Peck, Jessica C. Hassel
Publikováno v:
Cancer Research. 83:LB118-LB118
Background: Tebentafusp, a bispecific (gp100 x CD3) ImmTAC that can redirect T cells to target gp100+ melanoma cells, has shown a superior overall survival (OS) benefit compared to investigator choice for HLA-A*02:01+ patients (pts) with untreated me
Autor:
Alexander N. Shoushtari, Neil Steven, Cheryl McAlpine, Jeffrey R. Infante, Revashnee Naidoo, Sarah Stanhope, Ita O’Kelly, Omid Hamid, Victoria K Woodcock, Pippa Corrie, Mark R. Middleton, Emma Leach, Alan Anthoney, Sion Lewis, Jacob Hurst, Avinash Gupta, Antonella Vardeu, Thomas R. Jeffry Evans, Mario Sznol
Publikováno v:
Clinical Cancer Research. 26:5869-5878
Purpose: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain, which redirects T cells t
Autor:
Esra Güç, Sarah Stanhope, Koustubh Ranade, Rahul C. Khanolkar, Revashnee Naidoo, Adel Benlahrech, Laura C. Collins, Duncan Gascoyne, Emma Leach
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundImmTAC molecules are bispecific fusion proteins consisting of an affinity-enhanced T cell receptor fused to an anti-CD3 effector that can redirect T cells to target cells. Tebentafusp, a gp100-directed ImmTAC, has demonstrated survival bene